Clinical trial
A Phase 2b Randomized, Double-Masked, Sham-Controlled, Study to Evaluate the Efficacy and Safety of Intravitreal Injection of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
NCT04945772 is registered in ClinicalTrials.gov with Nanoscope Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b Randomized, Double-Masked, Sham-Controlled, Study to Evaluate the Efficacy and Safety of Intravitreal Injection of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
- Lead sponsor
- Nanoscope Therapeutics Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 13, 2021
- Completion date
- January 18, 2024
- Enrollment
- 27 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.